Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vactosertib Hydrochloride is an orally active and ATP-competitive ALK5 inhibitor (IC50: 12.9 nM). It has potently antimetastatic activity and anticancer effect. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC50: 17.3 nM).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 699 | 5日内发货 | ||
5 mg | ¥ 1,160 | 5日内发货 | ||
25 mg | ¥ 4,540 | 8-10周 | ||
50 mg | ¥ 5,820 | 8-10周 | ||
100 mg | ¥ 8,240 | 8-10周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 5日内发货 |
Vactosertib Hydrochloride 的其他形式现货产品:
产品描述 | Vactosertib Hydrochloride is an orally active and ATP-competitive ALK5 inhibitor (IC50: 12.9 nM). It has potently antimetastatic activity and anticancer effect. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC50: 17.3 nM). |
靶点活性 | ALK5:12.9 nM |
体外活性 | Vactosertib inhibits the TGFβ-induced nuclear translocation of Smad2/3 in 4T1 cells and MCF10A cells (IC50: 10-30 nM for Vactosertib on pSmad3 in 4T1 cells). Vactosertib (10-1000 nM; 30 minutes; 4T1 cells) treatment blocks the TGFβ-induced phosphorylation of Smad2 or Smad3 in a dose-dependent manner in 4T1 cells. Vactosertib abrogates TGFb1-induced tumor cell migration and invasion. Moreover, Vactosertib abolishes the TGFβ1-induced effects on genes related to epithelial-to-mesenchymal transition (EMT) [1]. |
体内活性 | Vactosertib inhibits the epithelial-to-mesenchymal transition (EMT) in both TGFβ-treated breast cancer cells and 4T1 orthotopic-grafted mice. Vactosertib (40 mg/kg; i.p.; every other day; for 10 weeks; MMTV/c-Neu female mice) treatment inhibits Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice. Vactosertib enhances cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice [1]. |
别名 | TEW-7197 Hydrochloride, EW-7197 Hydrochloride |
分子量 | 435.89 |
分子式 | C22H19ClFN7 |
CAS No. | 1352610-25-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (114.71 mM), Sonification is recommended.
DMSO: 50 mg/mL (114.71 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.2942 mL | 11.4708 mL | 22.9416 mL | 57.3539 mL |
5 mM | 0.4588 mL | 2.2942 mL | 4.5883 mL | 11.4708 mL | |
10 mM | 0.2294 mL | 1.1471 mL | 2.2942 mL | 5.7354 mL | |
20 mM | 0.1147 mL | 0.5735 mL | 1.1471 mL | 2.8677 mL | |
50 mM | 0.0459 mL | 0.2294 mL | 0.4588 mL | 1.1471 mL | |
100 mM | 0.0229 mL | 0.1147 mL | 0.2294 mL | 0.5735 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vactosertib Hydrochloride 1352610-25-3 Angiogenesis Tyrosine Kinase/Adaptors ALK EW 7197 Hydrochloride TEW-7197 Hydrochloride EW7197 Hydrochloride TEW 7197 Hydrochloride EW-7197 Hydrochloride TEW7197 Hydrochloride Inhibitor inhibitor inhibit